<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02161406</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-344</org_study_id>
    <secondary_id>1UM1AI110557</secondary_id>
    <nct_id>NCT02161406</nct_id>
  </id_info>
  <brief_title>A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis</brief_title>
  <acronym>ASSET</acronym>
  <official_title>A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dinesh Khanna, MD, MS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that SC abatacept is safe and shows evidence of efficacy (improvement
      in modified Rodnan score [mRSS]) in patients with diffuse cutaneous systemic sclerosis
      (dcScc) compared to matching placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized placebo-controlled double-blind phase 2 trial of patients with
      dcSSc. Eligible participants will be randomized in a 1:1 ratio to either 125 mg SC abatacept
      or matching placebo, stratified by duration of dcSSc disease duration (&lt;18 months vs &gt;18 to
      &lt;/=36 months). Study participants will be treated for 12 months on double-blind study
      medication, followed by an additional 24 weeks of open-label SC abatacept therapy. 86
      patients will be randomized in approximately 35 centers in the US, Canada and Europe, with
      the goal of analyzing 74 participants. The investigators study will test whether abatacept is
      statistically superior to placebo in reducing the MRSS at month 12 and explore the ability of
      abatacept to prevent or reverse progression in patients with early disease duration and lower
      MRSS scores, and reverse established disease in patients with longer disease duration and
      higher MRSS scores.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">October 17, 2018</completion_date>
  <primary_completion_date type="Actual">September 12, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants With at Least One Adverse Events (AEs) or Serious AEs (SAEs) in 1 Year</measure>
    <time_frame>52 weeks</time_frame>
    <description>Safety is measured using AEs, including clinical significant changes in vital signs, laboratory test abnormalities and clinical tolerability of abatacept, and using serious AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in the Modified Rodnan Skin Score (mRSS) to Month 12</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>The efficacy of treatment on skin fibrosis will be measured by changes from baseline to month 12 in mRSS, a measure of skin thickness. mRSS scores have a range from 0 to 51, with higher score indicating greater severity of SSc (worse outcome).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in Patient Global Assessment for Overall Disease</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Patient global assessment for overall disease represents the patient's assessment of the patient's global scleroderma on a 0 (excellent) -10 (extremely poor) Likert scale. Higher score means worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in Physician Global Assessment for Overall Disease</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>This assessment represents the physician's assessment of the patient's current disease activity on a 0 (excellent) -10 (extremely poor) Likert scale. Higher score means worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in % Predicted FVC</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>FVC is Forced vital capacity, a measure of lung function. FVC % Predicted is calculated using equations from Hankinson [Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159(1):179-87], incorporating age, gender, and race. It is calculated as the (FVC Observed / FVC predicted) * 100, where FVC predicted is calculated relative to a reference population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in FVC (in ml)</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>FVC = forced vital capacity, a measure of lung function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in HAQ-DI - Overall</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI overall score ranges from 0 (no disability) to 3 (severe disability). Higher score means worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in SHAQ-DI VAS - Overall Disease</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Scleroderma-Health Assessment Question Disability Index visual analogue scales (VAS) assess the burden of digital ulcers, Raynaud's, gastrointestinal involvement, breathing, and overall disease. The VAS scale for disease severity ranges from 0 (no disease) to 150 (very severe). A higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in SHAQ-DI VAS - Breathing</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Scleroderma-Health Assessment Question Disability Index visual analogue scales (VAS) assess the burden of digital ulcers, Raynaud's, gastrointestinal involvement, breathing, and overall disease. The VAS scale for how much breathing problems interfered with daily activities ranges from 0 (do not limit activities) to 150 (very severe limitation). A higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in SHAQ-DI VAS - Raynaud's</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Scleroderma-Health Assessment Question Disability Index visual analogue scales (VAS) assess the burden of digital ulcers, Raynaud's, gastrointestinal involvement, breathing, and overall disease. The VAS scale for how much Raynaud's interfered with daily activities ranges from 0 (does not limit activities) to 150 (very severe limitation). A higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in SHAQ-DI VAS - Burden of Digital Ulcers</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Scleroderma-Health Assessment Question Disability Index visual analogue scales (VAS) assess the burden of digital ulcers, Raynaud's, gastrointestinal involvement, breathing, and overall disease. The VAS scale for how much finger ulcers interfered with daily activities ranges from 0 (do not limit activities) to 150 (very severe limitation). A higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in SHAQ-DI VAS - GI Involvement</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Scleroderma-Health Assessment Question Disability Index visual analogue scales (VAS) assess the burden of digital ulcers, Raynaud's, gastrointestinal involvement, breathing, and overall disease. The VAS scale for how much intestinal problems interfered with daily activities ranges from 0 (do not limit activities) to 150 (very severe limitation). A higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in Swollen Joint Count</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>28 joints are assessed for swelling (positive or negative). The number of swollen joint count ranges from 0 to 28. A higher number indicates worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in Tender Joint Counts</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>28 joints are assessed for tenderness (positive or negative). The number of tender joint counts ranges from 0 to 28. A higher number indicates worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in PROMIS-29 - Physical Function</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the physical function domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., better outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in PROMIS-29 - Anxiety</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the anxiety domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in PROMIS-29 - Depression</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the depression domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in PROMIS 29 - Fatigue</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the fatigue domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in PROMIS-29 - Sleep Disturbance</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the sleep disturbance domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e.,worse outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in PROMIS-29 - Pain Interference</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the pain interference domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in PROMIS-29 - Ability to Participate in Social Roles &amp; Activities</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the ability to participate in social roles and activities domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., better outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in PROMIS-29 - Pain Intensity</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the pain intensity domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in SCTC GIT - Composite Score</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The SCTC GIT is the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Instrument. It assesses scleroderma-related gastrointestinal symptoms. The composite score ranges from 0 to 2.83; 0 indicates better health and higher score indicates worse health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR CRISS at 12 Months</measure>
    <time_frame>Week 52</time_frame>
    <description>The American College of Rheumatology Combined Response Index in Systemic Sclerosis is a composite endpoint. It is determined in a 2-step process. The first step assesses whether the patient has had a significant decline in renal or cardiopulmonary involvement. If none of these apply, the second step assesses the probability of improvement by measuring changes in five outcomes and integrating them into a single number using an equation described in Khanna D, Berrocal VJ, et al. [The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis and Rheumatology. 2016; 68(2):299-311.]. It incorporates changes in the modified Rodnan skin score, percent predicted forced vital capacity (FVC), patient and physician global assessments, and SHAQ-DI over 1 year. The score ranges from 0 to 1; a higher score indicates better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in PROMIS - Fatigue</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 8-question short-form health-reported quality of life measure fatigue domain was administered. The transformed score (T-score) was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in PROMIS - Sleep Disturbance</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 4-question short-form health-reported quality of life measure sleep disturbance domain was administered. The transformed score (T-score) was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., better outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in PROMIS - Sleep Impairment</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 8-question short-form health-reported quality of life measure sleep impairment domain was administered. The transformed score (T-score) was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in HAQ-DI - Dressing and Grooming</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in HAQ-DI - Hygiene</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in HAQ-DI - Arising</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in HAQ-DI - Reach</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in HAQ-DI - Eating</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in HAQ-DI - Grip</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in HAQ-DI - Walking</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in HAQ-DI - Common Daily Activities</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Diffuse Cutaneous Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Abatacept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>125mg Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
    <arm_group_label>Abatacept</arm_group_label>
    <other_name>Orencia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>125 mg of Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of Systematic Sclerosis (SSc), as defined using the 2013 American College of
             Rheumatology/ European Union League Against Rheumatism classification of SSc

          2. Diffuse Systemic Sclerosis (dcSSc) as defined by LeRoy and Medsger

          3. Disease duration of ≤ 36 months (defined as time from the first non−Raynaud phenomenon
             manifestation)

          4. For disease duration of ≤ 18 months: ≥ 10 and ≤ 35 mRSS units at the screening visit

          5. For disease duration of &gt;18-36 months: ≥ 15 and ≤ 45 mRSS units at the screening visit
             and one of the following:

               -  Increase ≥ 3 in mRSS units compared with the last visit within previous 1-6
                  months

               -  Involvement of one new body area with ≥ 2 mRSS units compared with the last visit
                  within the previous 1-6 months

               -  Involvement of two new body areas with ≥ 1 mRSS units compared with the last
                  visit within the previous 1-6 months

               -  Presence of 1 or more Tendon Friction Rub

          6. Age ≥ 18 years at the screening visit

          7. If female of childbearing potential, the patient must have a negative pregnancy test
             at screening and baseline visits

          8. Oral corticosteroids (≤ 10 mg/day of prednisone or equivalent) and NSAIDs are
             permitted if the patient is on a stable dose regimen for

               -  2 weeks prior to and including the baseline visit.

          9. ACE inhibitors, calcium-channel blockers, proton-pump inhibitors, and/or oral
             vasodilators are permitted if the patient is on a stable dose for ≥ 2 weeks prior to
             and including the baseline visit.

        Exclusion Criteria:

          1. Rheumatic disease other than dcSSc; it is acceptable to include patients with
             fibromyalgia and scleroderma-associated myopathy

          2. Limited cutaneous systemic sclerosis or sine scleroderma at the screening visit

          3. Major surgery (including joint surgery) within 8 weeks prior to screening visit

          4. Infected ulcer prior to randomization

          5. Treatment with any investigational agent within ≤ 4 weeks (or 5 half-lives of the
             investigational drug, whichever is longer) of the baseline visit

          6. Previous treatment with cell-depleting therapies, including investigational agents,
             including but not limited to, CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19, and
             ABA

          7. Anti-CD20, and cyclophosphamide within 12 months prior to baseline visit.

          8. Use of Intravenous Immunoglobulin (IVIG) within 12 weeks prior to baseline visit

          9. Previous treatment with chlorambucil, bone marrow transplantation, or total lymphoid
             irradiation

         10. Immunization with a live/attenuated vaccine within ≤ 4 weeks prior to the baseline
             visit

         11. Treatment with methotrexate, hydroxychloroquine, cyclosporine A, azathioprine,
             mycophenolate mofetil rapamycin, colchicine, or D-penicillamine, within≤ 4 weeks prior
             to the baseline visit

         12. Treatment with etanercept within ≤ 2 weeks, infliximab, certolizumab, golimumab, ABA
             or adalimumab within ≤ 8 weeks, anakinra within ≤ 1 week prior to the baseline visit

         13. Pulmonary disease with FVC ≤ 50% of predicted, or DLCO (uncorrected for hemoglobin ) ≤
             40% of predicted at the screening visit

         14. Pulmonary arterial hypertension (PAH) as determined by right heart catheterization or
             on PAH approved medications for PAH. It is acceptable to use PDFE-5 inhibitors for
             Raynaud's and digital ulcers.

         15. Subjects at risk for tuberculosis (TB). Specifically excluded from this study will be
             participants with a history of active TB within the last 3 years, even if it was
             treated; a history of active TB greater than 3 years ago, unless there is
             documentation that the prior anti-TB treatment was appropriate in duration and type;
             current clinical, radiographic, or laboratory evidence of active TB; and latent TB
             that was not successfully treated (≥ 4 weeks).

         16. Positive for hepatitis B surface antigen prior to the baseline visit

         17. Positive for hepatitis C antigen, if the presence of hepatitis C virus was also shown
             with polymerase chain reaction or recombinant immunoblot assay prior to baseline visit

         18. Subjects at risk for tuberculosis (TB). Specifically excluded from this study will be
             participants with a history of active TB within the last 3 years, even if it was
             treated; a history of active TB greater than 3 years ago, unless there is
             documentation that the prior anti-TB treatment was appropriate in duration and type;
             current clinical, radiographic, or laboratory evidence of active TB; and latent TB
             that was not successfully treated (≥ 4 weeks).

         19. Any of the following at the screening visit: Hemoglobin &lt;8.5 g/dL; WBC &lt; 3,000/mm3 (&lt;3
             x 109/L); platelets &lt; 100,000/mm3 (&lt;3 x 109/L); serum creatinine &gt; 2 x ULN; serum ALT
             or AST &gt; 2 x ULN

         20. Severe skin thickening (mRSS 3) on the inner aspects of thighs, upper arms, or abdomen

         21. Patients with a history of anaphylaxis to abatacept
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dinesh Khanna, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arthritis Associates of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California- Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harvard Mass General</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers University Clinical Research Center</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08831</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steffens Scleroderma Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthWell Health</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Health Services</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Health Care London</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.med.umich.edu/scleroderma</url>
    <description>To learn more about the Scleroderma program at the University of Michigan</description>
  </link>
  <link>
    <url>http://scleroderma-asset-study.org</url>
    <description>Study Website</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 3, 2014</study_first_submitted>
  <study_first_submitted_qc>June 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2014</study_first_posted>
  <results_first_submitted>April 4, 2019</results_first_submitted>
  <results_first_submitted_qc>May 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 18, 2019</results_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Dinesh Khanna, MD, MS</investigator_full_name>
    <investigator_title>Associate Professor of Rheumatology/ Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Scleroderma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 8, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT02161406/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT02161406/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Abatacept</title>
          <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>investigator withdrew subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>relocation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population includes all of the randomized participants who received at least one dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Abatacept</title>
          <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="88"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="12"/>
                    <measurement group_id="B2" value="49" spread="13"/>
                    <measurement group_id="B3" value="49" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Duration</title>
          <description>Disease duration for this outcome is defined as the disease duration since the first non-Raynaud's sign or symptom until the screening visit.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.66" spread="0.84"/>
                    <measurement group_id="B2" value="1.52" spread="0.79"/>
                    <measurement group_id="B3" value="1.59" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>dcSSc Disease Duration &lt;= 18 months</title>
          <description>dcSSc disease duration is defined as the time from the diagnosis of diffuse cutaneous systemic sclerosis (dcSSc) until screening.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>mRSS</title>
          <description>modified Rodnan skin scores (mRSS) have a range from 0 to 51, with higher score indicating greater severity of systemic scleroderma</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.34" spread="7.947"/>
                    <measurement group_id="B2" value="21.57" spread="7.328"/>
                    <measurement group_id="B3" value="22.45" spread="7.652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FVC% Predicted</title>
          <description>FVC is Forced vital capacity, a measure of lung function. FVC % Predicted is calculated using equations from Hankinson [Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159(1):179-87], incorporating age, gender, and race. It is calculated as the (FVC Observed / FVC predicted) * 100, where FVC predicted is calculated relative to a reference population.</description>
          <units>percent predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84.19" spread="13.504"/>
                    <measurement group_id="B2" value="86.49" spread="16.597"/>
                    <measurement group_id="B3" value="85.34" spread="15.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DLCO% Predicted, Corrected for Hemoglobin</title>
          <description>Percent predicted diffusing capacity for carbon monoxide (DLCO), corrected for hemoglobin (Hb), is reported. For adult males, the equation (expressing Hb in gm•dL-1) is DLCO predicted × (1.7*Hb / (10.22+Hb)). In adult women, the equation is DLCO predicted × (1.7*Hb / (9.38+Hb)). Percent predicted DLCO was entered directly into the eCRFs, based on equipment and testing techniques meeting ATS/ERS requirements (Crapo RO, Morris AH. Standardized single breath normal values for carbon monoxide diffusing capacity. Am.Rev.Respir.Dis 1981;123:185-189).</description>
          <units>percent predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.57" spread="18.117"/>
                    <measurement group_id="B2" value="76.45" spread="18.439"/>
                    <measurement group_id="B3" value="78.01" spread="18.241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient Global Assessment</title>
          <description>Patient global assessment for overall disease represents the patient’s assessment of the patient’s global scleroderma on a 0 (excellent) -10 (extremely poor) Likert scale.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.88" spread="2.206"/>
                    <measurement group_id="B2" value="4.31" spread="2.561"/>
                    <measurement group_id="B3" value="4.09" spread="2.384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HAQ-DI</title>
          <description>HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient’s functional ability. The HAQ-DI overall score ranges from 0 (no disability) to 3 (severe disability).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.14" spread="0.716"/>
                    <measurement group_id="B2" value="0.97" spread="0.701"/>
                    <measurement group_id="B3" value="1.05" spread="0.710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physician Global Assessment</title>
          <description>Physician global assessment for overall disease: This assessment represents the physician’s assessment of the patient’s current disease activity on a 0 (excellent) -10 (extremely poor) Likert scale.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.77" spread="1.669"/>
                    <measurement group_id="B2" value="4.76" spread="1.665"/>
                    <measurement group_id="B3" value="4.77" spread="1.657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Proportion of Participants with &gt;= 1 Tendon Friction Rubs</title>
          <description>Tendon friction rubs in systemic sclerosis have been associated with diffuse cutaneous skin disease, increased disability and poor survival. They were considered present if palpable on physical exam in the shoulder, elbow, wrist, metacarpophalangeal (MCP) joint, knee, and ankle. We report the proportion of subjects with at least one tendon friction rub.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Proportion of Participants with &gt;= 1 Large Joint Contractures</title>
          <description>Joint contractures are recognized by the loss of joint motion upon physical exam. We report the proportion of subjects with at least one large joint contracture.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Swollen Joint Count</title>
          <description>28 joints are assessed for swelling (positive or negative). The number of swollen joint count ranges from 0 to 28.</description>
          <units>number of swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.64" spread="5.620"/>
                    <measurement group_id="B2" value="3.86" spread="5.849"/>
                    <measurement group_id="B3" value="3.75" spread="5.704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Proportion of Participants with &gt;= 1 Swollen Joint Count</title>
          <description>28 joints are assessed for swelling (positive or negative). The number of swollen joint count ranges from 0 to 28. We report the proportion of participants with &gt;= 1 swollen joint.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Proportion of Participants with Previous Use of Immunosuppressives</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Proportion of Participants with Previous Use of Prednisone</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Participants With at Least One Adverse Events (AEs) or Serious AEs (SAEs) in 1 Year</title>
        <description>Safety is measured using AEs, including clinical significant changes in vital signs, laboratory test abnormalities and clinical tolerability of abatacept, and using serious AEs</description>
        <time_frame>52 weeks</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With at Least One Adverse Events (AEs) or Serious AEs (SAEs) in 1 Year</title>
          <description>Safety is measured using AEs, including clinical significant changes in vital signs, laboratory test abnormalities and clinical tolerability of abatacept, and using serious AEs</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Modified Rodnan Skin Score (mRSS) to Month 12</title>
        <description>The efficacy of treatment on skin fibrosis will be measured by changes from baseline to month 12 in mRSS, a measure of skin thickness. mRSS scores have a range from 0 to 51, with higher score indicating greater severity of SSc (worse outcome).</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Modified Rodnan Skin Score (mRSS) to Month 12</title>
          <description>The efficacy of treatment on skin fibrosis will be measured by changes from baseline to month 12 in mRSS, a measure of skin thickness. mRSS scores have a range from 0 to 51, with higher score indicating greater severity of SSc (worse outcome).</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.24" spread="1.14"/>
                    <measurement group_id="O2" value="-4.49" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in Patient Global Assessment for Overall Disease</title>
        <description>Patient global assessment for overall disease represents the patient's assessment of the patient's global scleroderma on a 0 (excellent) -10 (extremely poor) Likert scale. Higher score means worse outcome.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in Patient Global Assessment for Overall Disease</title>
          <description>Patient global assessment for overall disease represents the patient's assessment of the patient's global scleroderma on a 0 (excellent) -10 (extremely poor) Likert scale. Higher score means worse outcome.</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.423"/>
                    <measurement group_id="O2" value="-0.09" spread="0.457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in Physician Global Assessment for Overall Disease</title>
        <description>This assessment represents the physician's assessment of the patient's current disease activity on a 0 (excellent) -10 (extremely poor) Likert scale. Higher score means worse outcome.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in Physician Global Assessment for Overall Disease</title>
          <description>This assessment represents the physician's assessment of the patient's current disease activity on a 0 (excellent) -10 (extremely poor) Likert scale. Higher score means worse outcome.</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.290"/>
                    <measurement group_id="O2" value="-0.35" spread="0.318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in % Predicted FVC</title>
        <description>FVC is Forced vital capacity, a measure of lung function. FVC % Predicted is calculated using equations from Hankinson [Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159(1):179-87], incorporating age, gender, and race. It is calculated as the (FVC Observed / FVC predicted) * 100, where FVC predicted is calculated relative to a reference population.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in % Predicted FVC</title>
          <description>FVC is Forced vital capacity, a measure of lung function. FVC % Predicted is calculated using equations from Hankinson [Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159(1):179-87], incorporating age, gender, and race. It is calculated as the (FVC Observed / FVC predicted) * 100, where FVC predicted is calculated relative to a reference population.</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>percent predicted</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="1.24"/>
                    <measurement group_id="O2" value="-4.13" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in FVC (in ml)</title>
        <description>FVC = forced vital capacity, a measure of lung function</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in FVC (in ml)</title>
          <description>FVC = forced vital capacity, a measure of lung function</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>ml</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.39" spread="43.82"/>
                    <measurement group_id="O2" value="-121.6" spread="46.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in HAQ-DI - Overall</title>
        <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI overall score ranges from 0 (no disability) to 3 (severe disability). Higher score means worse outcome.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in HAQ-DI - Overall</title>
          <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI overall score ranges from 0 (no disability) to 3 (severe disability). Higher score means worse outcome.</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.07"/>
                    <measurement group_id="O2" value="0.11" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in SHAQ-DI VAS - Overall Disease</title>
        <description>Scleroderma-Health Assessment Question Disability Index visual analogue scales (VAS) assess the burden of digital ulcers, Raynaud's, gastrointestinal involvement, breathing, and overall disease. The VAS scale for disease severity ranges from 0 (no disease) to 150 (very severe). A higher score means a worse outcome.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in SHAQ-DI VAS - Overall Disease</title>
          <description>Scleroderma-Health Assessment Question Disability Index visual analogue scales (VAS) assess the burden of digital ulcers, Raynaud's, gastrointestinal involvement, breathing, and overall disease. The VAS scale for disease severity ranges from 0 (no disease) to 150 (very severe). A higher score means a worse outcome.</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.42" spread="5.638"/>
                    <measurement group_id="O2" value="3.52" spread="6.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in SHAQ-DI VAS - Breathing</title>
        <description>Scleroderma-Health Assessment Question Disability Index visual analogue scales (VAS) assess the burden of digital ulcers, Raynaud's, gastrointestinal involvement, breathing, and overall disease. The VAS scale for how much breathing problems interfered with daily activities ranges from 0 (do not limit activities) to 150 (very severe limitation). A higher score means a worse outcome.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in SHAQ-DI VAS - Breathing</title>
          <description>Scleroderma-Health Assessment Question Disability Index visual analogue scales (VAS) assess the burden of digital ulcers, Raynaud's, gastrointestinal involvement, breathing, and overall disease. The VAS scale for how much breathing problems interfered with daily activities ranges from 0 (do not limit activities) to 150 (very severe limitation). A higher score means a worse outcome.</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.30" spread="5.51"/>
                    <measurement group_id="O2" value="16.95" spread="5.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in SHAQ-DI VAS - Raynaud's</title>
        <description>Scleroderma-Health Assessment Question Disability Index visual analogue scales (VAS) assess the burden of digital ulcers, Raynaud's, gastrointestinal involvement, breathing, and overall disease. The VAS scale for how much Raynaud's interfered with daily activities ranges from 0 (does not limit activities) to 150 (very severe limitation). A higher score means a worse outcome.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in SHAQ-DI VAS - Raynaud's</title>
          <description>Scleroderma-Health Assessment Question Disability Index visual analogue scales (VAS) assess the burden of digital ulcers, Raynaud's, gastrointestinal involvement, breathing, and overall disease. The VAS scale for how much Raynaud's interfered with daily activities ranges from 0 (does not limit activities) to 150 (very severe limitation). A higher score means a worse outcome.</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.58" spread="6.60"/>
                    <measurement group_id="O2" value="-3.64" spread="7.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in SHAQ-DI VAS - Burden of Digital Ulcers</title>
        <description>Scleroderma-Health Assessment Question Disability Index visual analogue scales (VAS) assess the burden of digital ulcers, Raynaud's, gastrointestinal involvement, breathing, and overall disease. The VAS scale for how much finger ulcers interfered with daily activities ranges from 0 (do not limit activities) to 150 (very severe limitation). A higher score means a worse outcome.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in SHAQ-DI VAS - Burden of Digital Ulcers</title>
          <description>Scleroderma-Health Assessment Question Disability Index visual analogue scales (VAS) assess the burden of digital ulcers, Raynaud's, gastrointestinal involvement, breathing, and overall disease. The VAS scale for how much finger ulcers interfered with daily activities ranges from 0 (do not limit activities) to 150 (very severe limitation). A higher score means a worse outcome.</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.18" spread="5.13"/>
                    <measurement group_id="O2" value="8.67" spread="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in SHAQ-DI VAS - GI Involvement</title>
        <description>Scleroderma-Health Assessment Question Disability Index visual analogue scales (VAS) assess the burden of digital ulcers, Raynaud's, gastrointestinal involvement, breathing, and overall disease. The VAS scale for how much intestinal problems interfered with daily activities ranges from 0 (do not limit activities) to 150 (very severe limitation). A higher score means a worse outcome.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in SHAQ-DI VAS - GI Involvement</title>
          <description>Scleroderma-Health Assessment Question Disability Index visual analogue scales (VAS) assess the burden of digital ulcers, Raynaud's, gastrointestinal involvement, breathing, and overall disease. The VAS scale for how much intestinal problems interfered with daily activities ranges from 0 (do not limit activities) to 150 (very severe limitation). A higher score means a worse outcome.</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.98" spread="6.00"/>
                    <measurement group_id="O2" value="8.01" spread="6.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in Swollen Joint Count</title>
        <description>28 joints are assessed for swelling (positive or negative). The number of swollen joint count ranges from 0 to 28. A higher number indicates worse outcome.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in Swollen Joint Count</title>
          <description>28 joints are assessed for swelling (positive or negative). The number of swollen joint count ranges from 0 to 28. A higher number indicates worse outcome.</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>number of swollen joints</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.595"/>
                    <measurement group_id="O2" value="-0.86" spread="0.601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in Tender Joint Counts</title>
        <description>28 joints are assessed for tenderness (positive or negative). The number of tender joint counts ranges from 0 to 28. A higher number indicates worse outcome.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in Tender Joint Counts</title>
          <description>28 joints are assessed for tenderness (positive or negative). The number of tender joint counts ranges from 0 to 28. A higher number indicates worse outcome.</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>number of tender joints</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="0.90"/>
                    <measurement group_id="O2" value="-1.47" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in PROMIS-29 - Physical Function</title>
        <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the physical function domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., better outcome).</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in PROMIS-29 - Physical Function</title>
          <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the physical function domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., better outcome).</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.54" spread="0.65"/>
                    <measurement group_id="O2" value="-0.17" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in PROMIS-29 - Anxiety</title>
        <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the anxiety domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome).</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in PROMIS-29 - Anxiety</title>
          <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the anxiety domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome).</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="1.31"/>
                    <measurement group_id="O2" value="-1.09" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.21</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in PROMIS-29 - Depression</title>
        <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the depression domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome).</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in PROMIS-29 - Depression</title>
          <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the depression domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome).</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="1.13"/>
                    <measurement group_id="O2" value="-0.41" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.81</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in PROMIS 29 - Fatigue</title>
        <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the fatigue domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome).</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in PROMIS 29 - Fatigue</title>
          <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the fatigue domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome).</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="1.29"/>
                    <measurement group_id="O2" value="-0.98" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.86</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in PROMIS-29 - Sleep Disturbance</title>
        <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the sleep disturbance domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e.,worse outcome).</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in PROMIS-29 - Sleep Disturbance</title>
          <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the sleep disturbance domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e.,worse outcome).</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.57"/>
                    <measurement group_id="O2" value="-0.21" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.91</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in PROMIS-29 - Pain Interference</title>
        <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the pain interference domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome).</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in PROMIS-29 - Pain Interference</title>
          <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the pain interference domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome).</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.10" spread="1.13"/>
                    <measurement group_id="O2" value="-1.56" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in PROMIS-29 - Ability to Participate in Social Roles &amp; Activities</title>
        <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the ability to participate in social roles and activities domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., better outcome).</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in PROMIS-29 - Ability to Participate in Social Roles &amp; Activities</title>
          <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the ability to participate in social roles and activities domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., better outcome).</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.11" spread="1.07"/>
                    <measurement group_id="O2" value="-1.26" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.92</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in PROMIS-29 - Pain Intensity</title>
        <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the pain intensity domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome).</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in PROMIS-29 - Pain Intensity</title>
          <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the pain intensity domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome).</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="0.32"/>
                    <measurement group_id="O2" value="-0.18" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in SCTC GIT - Composite Score</title>
        <description>The SCTC GIT is the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Instrument. It assesses scleroderma-related gastrointestinal symptoms. The composite score ranges from 0 to 2.83; 0 indicates better health and higher score indicates worse health.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in SCTC GIT - Composite Score</title>
          <description>The SCTC GIT is the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Instrument. It assesses scleroderma-related gastrointestinal symptoms. The composite score ranges from 0 to 2.83; 0 indicates better health and higher score indicates worse health.</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.047"/>
                    <measurement group_id="O2" value="-0.05" spread="0.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR CRISS at 12 Months</title>
        <description>The American College of Rheumatology Combined Response Index in Systemic Sclerosis is a composite endpoint. It is determined in a 2-step process. The first step assesses whether the patient has had a significant decline in renal or cardiopulmonary involvement. If none of these apply, the second step assesses the probability of improvement by measuring changes in five outcomes and integrating them into a single number using an equation described in Khanna D, Berrocal VJ, et al. [The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis and Rheumatology. 2016; 68(2):299-311.]. It incorporates changes in the modified Rodnan skin score, percent predicted forced vital capacity (FVC), patient and physician global assessments, and SHAQ-DI over 1 year. The score ranges from 0 to 1; a higher score indicates better outcome.</description>
        <time_frame>Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>ACR CRISS at 12 Months</title>
          <description>The American College of Rheumatology Combined Response Index in Systemic Sclerosis is a composite endpoint. It is determined in a 2-step process. The first step assesses whether the patient has had a significant decline in renal or cardiopulmonary involvement. If none of these apply, the second step assesses the probability of improvement by measuring changes in five outcomes and integrating them into a single number using an equation described in Khanna D, Berrocal VJ, et al. [The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis and Rheumatology. 2016; 68(2):299-311.]. It incorporates changes in the modified Rodnan skin score, percent predicted forced vital capacity (FVC), patient and physician global assessments, and SHAQ-DI over 1 year. The score ranges from 0 to 1; a higher score indicates better outcome.</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" lower_limit=".005" upper_limit=".994"/>
                    <measurement group_id="O2" value="0.02" lower_limit="0" upper_limit="0.750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>van Elteren test</method>
            <method_desc>The van Elteren test adjusted for duration of dcSSc. Multiple imputation was used to address missing follow-up data in 5 components of CRISS.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in PROMIS - Fatigue</title>
        <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 8-question short-form health-reported quality of life measure fatigue domain was administered. The transformed score (T-score) was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome).</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in PROMIS - Fatigue</title>
          <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 8-question short-form health-reported quality of life measure fatigue domain was administered. The transformed score (T-score) was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome).</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.44" spread="1.209"/>
                    <measurement group_id="O2" value="-0.05" spread="1.285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1769</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in PROMIS - Sleep Disturbance</title>
        <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 4-question short-form health-reported quality of life measure sleep disturbance domain was administered. The transformed score (T-score) was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., better outcome).</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>Modified Intent-to-Treat population includes all of the randomized participants who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in PROMIS - Sleep Disturbance</title>
          <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 4-question short-form health-reported quality of life measure sleep disturbance domain was administered. The transformed score (T-score) was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., better outcome).</description>
          <population>Modified Intent-to-Treat population includes all of the randomized participants who received at least one dose of study medication</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.573"/>
                    <measurement group_id="O2" value="-0.21" spread="0.620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9075</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in PROMIS - Sleep Impairment</title>
        <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 8-question short-form health-reported quality of life measure sleep impairment domain was administered. The transformed score (T-score) was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome).</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>Modified Intent-to-Treat population includes all of the randomized participants who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in PROMIS - Sleep Impairment</title>
          <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) 8-question short-form health-reported quality of life measure sleep impairment domain was administered. The transformed score (T-score) was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome).</description>
          <population>Modified Intent-to-Treat population includes all of the randomized participants who received at least one dose of study medication</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="1.267"/>
                    <measurement group_id="O2" value="-0.54" spread="1.320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5831</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in HAQ-DI - Dressing and Grooming</title>
        <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in HAQ-DI - Dressing and Grooming</title>
          <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.115"/>
                    <measurement group_id="O2" value="0.14" spread="0.119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0193</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in HAQ-DI - Hygiene</title>
        <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in HAQ-DI - Hygiene</title>
          <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.125"/>
                    <measurement group_id="O2" value="0.40" spread="0.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0097</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in HAQ-DI - Arising</title>
        <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in HAQ-DI - Arising</title>
          <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.103"/>
                    <measurement group_id="O2" value="0.04" spread="0.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0751</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in HAQ-DI - Reach</title>
        <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in HAQ-DI - Reach</title>
          <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.176"/>
                    <measurement group_id="O2" value="0.03" spread="0.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4927</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in HAQ-DI - Eating</title>
        <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in HAQ-DI - Eating</title>
          <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.118"/>
                    <measurement group_id="O2" value="0.02" spread="0.122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1604</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in HAQ-DI - Grip</title>
        <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in HAQ-DI - Grip</title>
          <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.142"/>
                    <measurement group_id="O2" value="-0.22" spread="0.149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7281</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in HAQ-DI - Walking</title>
        <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in HAQ-DI - Walking</title>
          <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.100"/>
                    <measurement group_id="O2" value="0.18" spread="0.106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1679</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in HAQ-DI - Common Daily Activities</title>
        <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in HAQ-DI - Common Daily Activities</title>
          <description>The HAQ-DI is the Health Assessment Question Disability Index that assesses the extent of a patient's functional ability. The HAQ-DI subscore ranges from 0 (no disability) to 3 (severe disability). A higher score means worse outcome.</description>
          <population>mITT population includes all of the randomized participants who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.113"/>
                    <measurement group_id="O2" value="0.08" spread="0.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2906</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks</time_frame>
      <desc>Coding of adverse events into body system was performed by the study chair for adverse events and by the medical monitors for serious adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Abatacept</title>
          <description>125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
Abatacept: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>125mg Placebo
Placebo: 125 mg of Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>GAVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Digital Ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>NSTEMI Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pulmonary Arterial Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pulmonary Arterial Hypertension and Pericardial Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Worsening AV block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Dysphagia due to GI dysmotility</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Dysphagia from myositis and prolonged hospitalization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Erosive esophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>GAVE; Severe anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Melena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pseudo obstruction of the small bowel, paralytic ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis of right elbow</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Healthcare associated pneumonia (HCAP)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Left side mastoiditis/ abrythnitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma (BCC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma In-situ Left Anterior Ear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression with Suicidal Ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal crisis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Other Non-serious Adverse Events</sub_title>
                <description>Specific adverse event terms that occurred in &lt; 5% of subjects were pooled.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Other Non-serious Adverse Events</sub_title>
                <description>Specific adverse event terms that occurred in &lt; 5% of subjects were pooled.</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Other Non-serious Adverse Events</sub_title>
                <description>Specific adverse event terms that occurred in &lt; 5% of subjects were pooled.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Other Non-serious Adverse Events</sub_title>
                <description>Specific adverse event terms that occurred in &lt; 5% of subjects were pooled.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other Non-serious Adverse Events</sub_title>
                <description>Specific adverse event terms that occurred in &lt; 5% of subjects were pooled.</description>
                <counts group_id="E1" events="17" subjects_affected="11" subjects_at_risk="44"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Vomiting (Emesis)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other Non-serious Adverse Events</sub_title>
                <description>Specific adverse event terms that occurred in &lt; 5% of subjects were pooled.</description>
                <counts group_id="E1" events="23" subjects_affected="13" subjects_at_risk="44"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Other Non-serious Adverse Events</sub_title>
                <description>Specific adverse event terms that occurred in &lt; 5% of subjects were pooled.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Other Non-serious Adverse Events</sub_title>
                <description>Specific adverse event terms that occurred in &lt; 5% of subjects were pooled.</description>
                <counts group_id="E1" events="24" subjects_affected="17" subjects_at_risk="44"/>
                <counts group_id="E2" events="39" subjects_affected="22" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Other Non-serious Adverse Events</sub_title>
                <description>Specific adverse event terms that occurred in &lt; 5% of subjects were pooled.</description>
                <counts group_id="E1" events="25" subjects_affected="18" subjects_at_risk="44"/>
                <counts group_id="E2" events="23" subjects_affected="17" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Other Non-serious Adverse Events</sub_title>
                <description>Specific adverse event terms that occurred in &lt; 5% of subjects were pooled.</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Other Non-serious Adverse Events</sub_title>
                <description>Specific adverse event terms that occurred in &lt; 5% of subjects were pooled.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other Non-serious Adverse Events</sub_title>
                <description>Specific adverse event terms that occurred in &lt; 5% of subjects were pooled.</description>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Other Non-serious Adverse Events</sub_title>
                <description>Specific adverse event terms that occurred in &lt; 5% of subjects were pooled.</description>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pruritis (Itching)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Cathie Spino</name_or_title>
      <organization>University of Michigan DCC (SABER)</organization>
      <phone>734-615-5469</phone>
      <email>spino@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

